UGL vs. CURE
UGL (ProShares Ultra Gold) and CURE (Direxion Daily Healthcare Bull 3x Shares) are both exchange-traded funds - UGL is a Leveraged Commodities fund tracking the Bloomberg Gold Subindex (200%), while CURE is a Leveraged Equities fund tracking the Health Care Select Sector Index (300%). Both are passively managed. Over the past 10 years, UGL returned 16.37%/yr vs 13.49%/yr for CURE. At a 0.03 correlation, their price movements are largely independent. UGL charges 0.95%/yr vs 1.08%/yr for CURE.
Performance
UGL vs. CURE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, UGL achieves a -12.66% return, which is significantly lower than CURE's -7.96% return. Over the past 10 years, UGL has outperformed CURE with an annualized return of 16.37%, while CURE has yielded a comparatively lower 13.49% annualized return.
UGL
- 1D
- 0.08%
- 1M
- -20.27%
- YTD
- -12.66%
- 6M
- -12.99%
- 1Y
- 32.76%
- 3Y*
- 47.90%
- 5Y*
- 24.60%
- 10Y*
- 16.37%
CURE
- 1D
- -0.55%
- 1M
- 13.53%
- YTD
- -7.96%
- 6M
- -6.00%
- 1Y
- 26.46%
- 3Y*
- 3.05%
- 5Y*
- 1.51%
- 10Y*
- 13.49%
UGL vs. CURE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
UGL ProShares Ultra Gold | -12.66% | 137.57% | 46.36% | 15.56% | -7.59% | -12.30% | 39.04% | 31.11% | -8.02% | 22.50% |
CURE Direxion Daily Healthcare Bull 3x Shares | -7.96% | 22.55% | -8.47% | -9.40% | -20.51% | 88.30% | 5.02% | 55.66% | 2.82% | 69.32% |
Correlation
The correlation between UGL and CURE is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.11 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.06 |
Correlation (All Time) Calculated using the full available price history since Jun 15, 2011 | 0.03 |
The correlation between UGL and CURE shifts across timeframes, from 0.03 (all time) to 0.17 (1 year), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
UGL vs. CURE — Risk / Return Rank
UGL
CURE
UGL vs. CURE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Gold (UGL) and Direxion Daily Healthcare Bull 3x Shares (CURE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| UGL | CURE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.01 | ||
| Sortino ratioReturn per unit of downside risk | -0.11 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.13 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 0.71 | 0.85 | -0.15 |
| Martin ratioReturn relative to average drawdown | 1.85 | 1.94 | -0.09 |
Loading charts...
Drawdowns
UGL vs. CURE - Drawdown Comparison
The maximum UGL drawdown since its inception was -75.93%, which is greater than CURE's maximum drawdown of -69.19%. Use the drawdown chart below to compare losses from any high point for UGL and CURE.
Loading charts...
Drawdown Indicators
| UGL | CURE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.93% | -69.19% | -6.74% |
Max Drawdown (1Y)Largest decline over 1 year | -46.64% | -31.10% | -15.54% |
Max Drawdown (3Y)Largest decline over 3 years | -46.64% | -51.93% | +5.29% |
Max Drawdown (5Y)Largest decline over 5 years | -46.64% | -52.23% | +5.59% |
Max Drawdown (10Y)Largest decline over 10 years | -46.64% | -69.19% | +22.55% |
Current DrawdownCurrent decline from peak | -43.37% | -26.94% | -16.43% |
Average DrawdownAverage peak-to-trough decline | -43.62% | -18.16% | -25.46% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.76% | 13.71% | +4.05% |
Volatility
UGL vs. CURE - Volatility Comparison
ProShares Ultra Gold (UGL) has a higher volatility of 15.51% compared to Direxion Daily Healthcare Bull 3x Shares (CURE) at 14.30%. This indicates that UGL's price experiences larger fluctuations and is considered to be riskier than CURE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| UGL | CURE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.51% | 14.30% | +1.21% |
Volatility (6M)Calculated over the trailing 6-month period | 48.64% | 30.87% | +17.77% |
Volatility (1Y)Calculated over the trailing 1-year period | 54.39% | 44.32% | +10.07% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 36.61% | 43.84% | -7.23% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.58% | 49.59% | -17.01% |
UGL vs. CURE - Expense Ratio Comparison
UGL has a 0.95% expense ratio, which is lower than CURE's 1.08% expense ratio.
Dividends
UGL vs. CURE - Dividend Comparison
UGL has not paid dividends to shareholders, while CURE's dividend yield for the trailing twelve months is around 1.16%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
CURE Direxion Daily Healthcare Bull 3x Shares | 1.16% | 1.12% | 1.17% | 2.02% | 0.38% | 0.02% | 0.17% | 0.40% | 0.70% | 0.18% |
UGL ProShares Ultra Gold | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
UGL and CURE have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
UGL has higher volatility (15.51%) compared to CURE (14.30%). In terms of maximum drawdown, UGL dropped -75.93% vs CURE's -69.19%.
On 10-year performance, UGL leads with 16.37% vs 13.49% for CURE. On fees, UGL is cheaper at 0.95% per year. On volatility, CURE has been the lower-risk option at 14.30%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, UGL has performed better with a 16.37% return vs 13.49%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
UGL is cheaper with a 0.95% expense ratio, compared with 1.08% for CURE.
CURE has the higher dividend yield at 1.16%, compared with 0.00% for UGL.
UGL is categorized as Leveraged Commodities, while CURE is Leveraged Equities. UGL tracks Bloomberg Gold Subindex (200%), while CURE tracks Health Care Select Sector Index (300%). They also come from different issuers: ProShares and Direxion. Their fees differ too: 0.95% for UGL and 1.08% for CURE.
UGL currently has the higher Sharpe Ratio (0.61 vs 0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for UGL and CURE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer